Fig. 2: Study characteristics of all included studies. | Communications Medicine

Fig. 2: Study characteristics of all included studies.

From: Preclinical extracellular matrix-based treatment strategies for myocardial infarction: a systematic review and meta-analysis

Fig. 2

Percent distribution of (a) animal models, (b) sex of animal models, (c) disease models, (d) method of administration, (e) method of functional outcome measurement, (f) timing of treatment, and (g) ECM source. For timing of treatment “Early” denotes treatment administration within the 1st day following implementation of infarction, “Mid” treatment within 7 days, and “late” treatment administration after 7 days. N number represents number of studies. ECM extracellular matrix, NR not reported, IR ischemia reperfusion, MI myocardial infarction, ECHO echocardiography, MRI magnetic resonance imaging, PV pressure-volume, NA not applicable, HAPLN1 Hyaluronan And Proteoglycan Link Protein 1, HA hyaluronic acid, dECM decellularized extracellular matrix.

Back to article page